Abstract
Current gold standard approaches to the treatment of depression include pharmacotherapeutic and psychotherapeutic interventions with social support. Due to current controversies concerning the efficacy of antidepressants in randomized controlled trials, the generalizability of study findings to wider clinical practice and the increasing importance of socioeconomic considerations, it seems timely to address the uncertainty of concerned patients and relatives, and their treating psychiatrists and general practitioners. We therefore discuss both the efficacy and clinical effectiveness of antidepressants in the treatment of depressive disorders. We explain and clarify useful measures for assessing clinically meaningful antidepressant treatment effects and the types of studies that are useful for addressing uncertainties. This includes considerations of methodological issues in randomized controlled studies, meta-analyses, and effectiveness studies. Furthermore, we summarize the differential efficacy and effectiveness of antidepressants with distinct pharmacodynamic properties, and differences between studies using antidepressants and/or psychotherapy. We also address the differential effectiveness of antidepressant drugs with differing modes of action and in varying subtypes of depressive disorder. After highlighting the clinical usefulness of treatment algorithms and the divergent biological, psychological, and clinical efforts to predict the effectiveness of antidepressant treatments, we conclude that the spectrum of different antidepressant treatments has broadened over the last few decades. The efficacy and clinical effectiveness of antidepressants is statistically significant, clinically relevant, and proven repeatedly. Further optimization of treatment can be helped by clearly structured treatment algorithms and the implementation of psychotherapeutic interventions. Modern individualized antidepressant treatment is in most cases a well-tolerated and efficacious approach to minimize the negative impact of otherwise potentially devastating and life-threatening outcomes in depressive disorders.
Notes
Augmentation treatment: efficiency amplification of an antidepressant treatment with a substance that alone does not exert sufficient antidepressant activity to be used as a monotherapy.
The mode of action of bupropion is discussed as a dopamine and noradrenaline reuptake inhibitor (DNRI), but there are now four PET scan studies in humans showing only a ~20% occupation of dopamine transporters with clinically relevant doses and no clear evidence of NE reuptake inhibition. This may be due to the fact that its affinity is 10–100 times less for the NE transporter than the DA transporter in rodents [135]. Nevertheless, it increases both norepinephrine and serotonin transmission [169].
References
Adli M, Bauer M, Rush AJ (2006) Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry 59:1029–1038
Adli M, Berghofer A, Linden M, Helmchen H, Müller-Oerlinghausen B, Mackert A, Stamm T, Bauer M (2002) Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Psychiatry 63:782–790
Adli M, Rush AJ, Möller HJ, Bauer M (2003) Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry 36(Suppl 3):S222–S229
Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26:607–611
Akiskal H, Bourgeois ML, Angst J, Post R, Möller H-J, Hirschfeld RM (2000) Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 59(Suppl 1):5–30
Akiskal HS, Benazzi F (2005) Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II? J Affect Disord 84:209–217
Akiskal HS, Benazzi F (2006) The DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: evidence that they lie on a dimensional spectrum. J Affect Disord 92:45–54
Akiskal HS, Benazzi F (2008) Continuous distribution of atypical depressive symptoms between major depressive and bipolar II disorders: dose-response relationship with bipolar family history. Psychopathology 41:39–42
Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC (2001) Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 158:1617–1622
Altshuler LL, Frye MA, Gitlin MJ (2003) Acceleration and augmentation strategies for treating bipolar depression. Biol Psychiatry 53:691–700
Altshuler LL, Post RM, Black DO, Keck PE Jr, Nolen WA, Frye MA, Suppes T, Grunze H, Kupka RW, Leverich GS, McElroy SL, Walden J, Mintz J (2006) Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry 67:1551–1560
Altshuler LL, Post RM, Hellemann G, Leverich GS, Nolen WA, Frye MA, Keck PE Jr, Kupka RW, Grunze H, McElroy SL, Sugar CA, Suppes T (2009) Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry 70:450–457
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4 ed rev. American Psychiatric Association, Washington
American Psychiatric Association Committee on Electroconvulsive Therapy, Weiner RD, Coffey CE, Folk J, Fochtmann LJ, Greenberg RM, Isenberg KE, Kellner CH, Sackeim HA, Moench LM (2001) The practice of electroconvulsive therapy. American Psychiatric Association, Washington
Amrein R, Stabl M, Henauer S, Affolter E, Jonkanski I (1997) Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview. Can J Psychiatry 42:1043–1050
Amsterdam JD, Garcia-Espana F (2000) Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 59:225–229
Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Schweizer E, Beasley C (1998) Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 18:435–440
Amsterdam JD, Hornig-Rohan M (1996) Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 19:371–386
Amsterdam JD, Shults J (2005) Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression—lack of manic induction. J Affect Disord 87:121–130
Anderson IM (1998) SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7(Suppl 1):11–17
Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19–36
Andrews JM, Nemeroff CB (1994) Contemporary management of depression. Am J Med 97:24S–32S
Angst J (2006) Do many patients with depression suffer from bipolar disorder? Can J Psychiatry 51:3–5
Angst J, Angst F, Gerber-Werder R, Gamma A (2005) Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years’ follow-up. Arch Suicide Res 9:279–300
Angst J, Dobler-Mikola A (1985) The Zurich study—a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. IV. Recurrent and nonrecurrent brief depression. Eur Arch Psychiatry Neurol Sci 234:408–416
Angst J, Gamma A, Benazzi F, Ajdacic V, Rössler W (2007) Melancholia and atypical depression in the Zurich study: epidemiology, clinical characteristics, course, comorbidity and personality. Acta Psychiatr Scand 115:72–84
Angst J, Gamma A, Pezawas L, jdacic-Gross V, Eich D, Rossler W, Altamura C (2007) Parsing the clinical phenotype of depression: the need to integrate brief depressive episodes. Acta Psychiatr Scand 115:221–228
Angst J, Sellaro R, Stassen HH, Gamma A (2005) Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J Affect Disord 84:149–157
Anton RF Jr, Burch EA Jr (1990) Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 147:1203–1208
Armitage R (2007) Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand 115:104–115
Aronson R, Offman HJ, Joffe RT, Naylor CD (1996) Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 53:842–848
Arranz MJ, Kapur S (2008) Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 34:1130–1144
Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N, Macgillivray S (2009) Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev CD007954
Azorin JM, Llorca PM, Despiegel N, Verpillat P (2004) Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale 30:158–166
Baghai TC, Binder EB, Schule C, Salyakina D, Eser D, Lucae S, Zwanzger P, Haberger C, Zill P, Ising M, Deiml T, Uhr M, Illig T, Wichmann HE, Modell S, Nothdurfter C, Holsboer F, Muller-Myhsok B, Möller HJ, Rupprecht R, Bondy B (2006) Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 11:1003–1015
Baghai TC, Marcuse A, Brosch M, Schule C, Eser D, Nothdurfter C, Steng Y, Noack I, Pietschmann K, Möller HJ, Rupprecht R (2006) The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry 7:82–90
Baghai TC, Möller H-J, Rupprecht R (2006) Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharm Des 12:503–515
Baghai TC, Schule C, Zill P, Deiml T, Eser D, Zwanzger P, Ella R, Rupprecht R, Bondy B (2004) The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci Lett 363:38–42
Baghai TC, Schüle C, Zwanzger P, Minov C, Holme C, Padberg F, Bidlingmaier M, Strasburger CJ, Rupprecht R (2002) Evaluation of a salivary based combined dexamethasone/CRH test in patients with major depression. Psychoneuroendocrinology 27:385–399
Baghai TC, Schüle C, Zwanzger P, Minov C, Schwarz MJ, de Jonge S, Rupprecht R, Bondy B (2001) Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry 6:258–259
Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ (2003) Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 253:22–28
Barbato A, D’Avanzo B (2006) Marital therapy for depression. Cochrane Database Syst Rev CD004188
Barbato A, D’Avanzo B (2008) Efficacy of couple therapy as a treatment for depression: a meta-analysis. Psychiatr Q 79:121–132
Barbui C, Furukawa TA, Cipriani A (2008) Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008(01/30):296–305
Bares M, Brunovsky M, Kopecek M, Novak T, Stopkova P, Kozeny J, Sos P, Krajca V, Hoschl C (2008) Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur Psychiatry 23:350–355
Barkin RL, Barkin S (2005) The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 12:431–438
Bauer M, Adli M, Baethge C, Berghofer A, Sasse J, Heinz A, Bschor T (2003) Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 48:440–448
Bauer M, Bschor T, Kunz D, Berghofer A, Strohle A, Müller-Oerlinghausen B (2000) Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 157:1429–1435
Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Möller HJ (2007) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8:67–104
Bauer M, Döpfmer S (1999) Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19:427–434
Bauer M, Pfennig A, Linden M, Smolka MN, Neu P, Adli M (2009) Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. J Clin Psychopharmacol 29:327–333
Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70:540–549
Bauer M, Tharmanathan P, Volz HP, Möller HJ, Freemantle N (2009) The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 259:172–185
Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ (2002) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3:69–86
Bauer M, Whybrow PC, Angst J, Versiani M, Möller H-J, WFSBP Task Force on Tretment Guidelines for Unipolar Depressive Disorders (2002) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorder, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:4–43
Bech P (2001) Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton depression scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 2002(01/25):337–345
Bech P (2004) Modern psychometrics in clinimetrics: impact on clinical trials of antidepressants. Psychother Psychosom 2004(03/20):134–138
Bech P (2006) Rating scales in depression: limitations and pitfalls. Dialogues Clin Neurosci 2006(08/08):207–215
Bech P (2010) Is the antidepressive effect of second-generation antidepressants a myth? Psychol Med 2009(06/06):181–186
Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O, Nagy A (1981) The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 63:290–299
Bech P, Tanghoj P, Cialdella P, Andersen HF, Pedersen AG (2004) Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004(08/24):283–290
Belmaker RH (2007) Treatment of bipolar depression. N Engl J Med 356:1771–1773
Benkert O, Grunder G, Wetzel H, Hackett D (1996) A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 30:441–451
Benkert O, Szegedi A, Kohnen R (2000) Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61:656–663
Berger M, Brakemeier EL, Klesse C, Schramm E (2009) Affective disorders. The significance of psychotherapeutic approaches. Nervenarzt 80:540, 542–540, 548
Birkenhager TK, Renes JW, Pluijms EM (2004) One-year follow-up after successful ECT: a naturalistic study in depressed inpatients. J Clin Psychiatry 65:87–91
Bland JM, Altman DG (1994) Regression towards the mean. BMJ 308:1499
Bland JM, Altman DG (1994) Some examples of regression towards the mean. BMJ 309:780
Blier P, Abbott FV (2001) Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 26:37–43
Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hebert C, Debonnel G (2009) Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 19:457–465
Blier P, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Debonnel G (2007) Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol 10:41–50
Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R (2010) Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167:281–288
Bortolotti B, Menchetti M, Bellini F, Montaguti MB, Berardi D (2008) Psychological interventions for major depression in primary care: a meta-analytic review of randomized controlled trials. Gen Hosp Psychiatry 30:293–302
Bosmans JE, van Schaik DJ, de Bruijne MC, van Hout HP, van Marwijk HW, van Tulder MW, Stalman WA (2008) Are psychological treatments for depression in primary care cost-effective? J Ment Health Policy Econ 11:3–15
Brockmann H, Zobel A, Joe A, Biermann K, Scheef L, Schuhmacher A, von Widdern O, Metten M, Biersack HJ, Maier W, Boecker H (2009) The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression. Psychiatry Res 173:107–112
Broich K (2009) Committee for medicinal products for human use (CHMP) assessment on efficacy of antidepressants. Eur Neuropsychopharmacol 2009(03/10):305–308
Brouwer JP, Appelhof BC, Peeters RP, Hoogendijk WJ, Huyser J, Schene AH, Tijssen JG, Van DR, Visser TJ, Wiersinga WM, Fliers E (2006) Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression. Eur J Endocrinol 154:819–825
Brown EB, McElroy SL, Keck PE Jr, Deldar A, Adams DH, Tohen M, Williamson DJ (2006) A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 67:1025–1033
Brown WA (2007) Treatment response in melancholia. Acta Psychiatr Scand 115:125–129
Browne G, Steiner M, Roberts J, Gafni A, Byrne C, Dunn E, Bell B, Mills M, Chalklin L, Wallik D, Kraemer J (2002) Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord 68:317–330
Bschor T, Baethge C, Adli M, Eichmann U, Ising M, Uhr M, Modell S, Kunzel H, Muller-Oerlinghausen B, Bauer M (2003) Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder. J Psychiatr Res 37:135–143
Bschor T, Bauer M (2006) Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 12:2985–2992
Burrows GD, Norman TR, Judd FK (1994) Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol 9(Suppl 2):5–10
Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 study group. J Clin Psychiatry 60:79–88
Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan ET, Leadbetter RA (2008) Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 10:323–333
Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J (2005) A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351–1360
Carreira K, Miller MD, Frank E, Houck PR, Morse JQ, Dew MA, Butters’ MA, Reynolds CF III (2008) A controlled evaluation of monthly maintenance interpersonal psychotherapy in late-life depression with varying levels of cognitive function. Int J Geriatr Psychiatry 23:1110–1113
Casey P (2009) Adjustment disorder: epidemiology, diagnosis and treatment. CNS Drugs 23:927–938
Cassano GB, Musetti L, Perugi G, Soriani A, Mignani V, McNair DM, Akiskal HS (1988) A proposed new approach to the clinical subclassification of depressive illness. Pharmacopsychiatry 21:19–23
Charney DS, Grothe DR, Smith SL, Brady KT, Kaltsounis-Puckett J, Wright CW, Laird LK, Rush AJ (2002) Overview of psychiatric disorders and the role of newer antidepressants. J Clin Psychiatry 63:3–9
Cipriani A, Barbui C, Brambilla P, Furukawa TA, Hotopf M, Geddes JR (2006) Are all antidepressants really the same? The case of fluoxetine: a systematic review. J Clin Psychiatry 67:850–864
Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C (2005) Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 19:CD004185
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758
Cipriani A, La FT, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C (2009) Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev CD006117
Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C (2009) Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev CD006532
Citrome L (2008) Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 117:412–419
Cohn JB, Collins G, Ashbrook E, Wernicke JF (1989) A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 4:313–322
Collier DA, Stober G, Li T, Heils A, Catalano M, Di BD, Arranz MJ, Murray RM, Vallada HP, Bengel D, Muller CR, Roberts GW, Smeraldi E, Kirov G, Sham P, Lesch KP (1996) A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1:453–460
Conte HR, Plutchik R, Wild KV, Karasu TB (1986) Combined psychotherapy and pharmacotherapy for depression. A systematic analysis of the evidence. Arch Gen Psychiatry 43:471–479
Cook RJ, Sackett DL (1995) The number needed to treat: a clinically useful measure of treatment effect. BMJ 310:452–454
Coryell W (1996) Psychotic depression. J Clin Psychiatry 57(Suppl 3):27–31
Coryell W (1998) The treatment of psychotic depression. J Clin Psychiatry 59(Suppl 1):22–27
Coryell W (2007) The facets of melancholia. Acta Psychiatr Scand 115:31–36
Cournoyer G, de Montigny C, Ouellette J, Langlois R, Elie R, Caille G, le Morvan P (1987) A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. J Clin Psychopharmacol 7:385–393
Cowen PJ (2009) Commentary on STAR*D: a summary and UK perspective. J Psychopharmacol 23:618–619
Crossley NA, Bauer M (2007) Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 68:935–940
Croxtall JD, Scott LJ (2010) Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 24:245–262
Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E (2009) Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 13:5–14
Cuijpers P, Dekker J, Hollon SD, Andersson G (2009) Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry 70:1219–1229
Cuijpers P, van Straten A, van Oppen P, Andersson G (2008) Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry 69:1675–1685
Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Astrom M, Brecher M (2009) Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 70:526–539
Dam J, Ryde L, Svejso J, Lauge N, Lauritsen B, Bech P (1998) Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 31:48–54
Danish University Antidepressant Group (1993) Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 28:105–116
Davidson JR, McLeod MN, Turnbull CD, Miller RD (1981) A comparison of phenelzine and imipramine in depressed inpatients. J Clin Psychiatry 42:395–397
Davidson JR, Miller RD, Turnbull CD, Sullivan JL (1982) Atypical depression. Arch Gen Psychiatry 39:527–534
Davis LL, Bartolucci A, Petty F (2005) Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 85:259–266
De la Fuente JM (2008) Case report: excellent response to long-term higher dose single olanzapine in a case of recurrent brief depression. Pharmacopsychiatry 41:156–158
de la Gandara J, Rojo JE, Ros S, Aguera L, de Pedro JM (2005) Neuropharmacological basis of combining antidepressants. Acta Psychiatr Scand Suppl 11–3:36
de Mello MF, de Jesus MJ, Bacaltchuk J, Verdeli H, Neugebauer R (2005) A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci 255:75–82
De BD, Di IG, Acciavatti T, Conti C, Serroni N, Olivieri L, Cavuto M, Martinotti G, Janiri L, Moschetta FS, Conti P, Di GM (2011) The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 10:119–132
Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P (2007) Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 10:51–61
Dekker JJ, Koelen JA, Van HL, Schoevers RA, Peen J, Hendriksen M, Kool S, Van AG, De JF (2008) Speed of action: the relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment algorithm for depression. J Affect Disord 109:183–188
Derry S, Moore RA (2007) Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 7:40
DeRubeis RJ, Gelfand LA, Tang TZ, Simons AD (1999) Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 156:1007–1013
DeRubeis RJ, Siegle GJ, Hollon SD (2008) Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci 9:788–796
DGPPN (2009) http://www.versorgungsleitlinien.de. Accessed 10 Dec 2009
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793–802
Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr (2010) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71:1605–1611
Dodd S, Berk M (2008) Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. Expert Rev Neurother 8:1299–1306
Dodd S, Horgan D, Malhi GS, Berk M (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89:1–11
Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M (2007) Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar disorders 9:618–627
ECT review group (2003) Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361:799–808
Edelsberg J, Oster G (2009) Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain? Eur J Pain 13:11–16
Eitan R, Lerer B (2006) Nonpharmacological, somatic treatments of depression: electroconvulsive therapy and novel brain stimulation modalities. Dialogues Clin Neurosci 8:241–258
El Mansari M, Ghanbari R, Janssen S, Blier P (2008) Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology 55:1191–1198
El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13:917–932
Elkin I, Gibbons RD, Shea MT, Sotsky SM, Watkins JT, Pilkonis PA, Hedeker D (1995) Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 63:841–847
Ellis P (2004) Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 38:389–407
Eser D, Baghai TC, Moller HJ (2010) Agomelatine: the evidence for its place in the treatment of depression. Core Evid 4:171–179
Euromean Medicines Agency (EMA) (17-9-2009) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004861.pdf. Accessed 1 Feb 2011
Faltermaier-Temizel M, Laakmann G, Baghai T, Kuhn K (1997) Predictive factors for therapeutic success in depressive syndrome. Nervenarzt 68:62–66
Fava GA (2003) Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 64:123–133
Fava M (2002) Somatic symptoms, depression, and antidepressant treatment. J Clin Psychiatry 63:305–307
Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649–659
Fava M (2003) The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry 64(Suppl 13):26–29
Fava M, Davidson KG (1996) Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179–200
Fava M, Evins AE, Dorer DJ, Schoenfeld DA (2003) The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72:115–127
Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH (2006) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163:1161–1172
Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ (2001) Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 103:66–72
Fink M (1990) Is catatonia a primary indication for ECT? Convuls Ther 6:1–4
Fink M (1992) Catatonia and DSM-IV. Convuls Ther 8:159–162
Fink M, Taylor MA (2007) Resurrecting melancholia. Acta Psychiatr Scand 115:14–20
Fountoulakis KN, Iacovides A, Nimatoudis I, Kaprinis G, Ierodiakonou C (1999) Comparison of the diagnosis of melancholic and atypical features according to DSM-IV and somatic syndrome according to ICD-10 in patients suffering from major depression. Eur Psychiatry 14:426–433
Fountoulakis KN, Möller HJ (2010) Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14:405–412
Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303:47–53
Frank E, Grochocinski VJ, Spanier CA, Buysse DJ, Cherry CR, Houck PR, Stapf DM, Kupfer DJ (2000) Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. J Clin Psychiatry 61:51–57
Frank E, Kupfer DJ, Buysse DJ, Swartz HA, Pilkonis PA, Houck PR, Rucci P, Novick DM, Grochocinski VJ, Stapf DM (2007) Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. Am J Psychiatry 164:761–767
Frank E, Novick D (2001) Progress in the psychotherapy of mood disorders: studies from the Western Psychiatric Institute and Clinic. Epidemiol Psichiatr Soc 10:245–252
Fritze J, Möller HJ (2001) Design of clinical trials of antidepressants: should a placebo control arm be included? CNS Drugs 15:755–764
Frye MA (2011) Clinical practice. Bipolar disorder—a focus on depression. N Engl J Med 364:51–59
Gajwani P, Muzina DJ, Kemp DE, Gao K, Calabrese JR (2007) Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies. Neuropsychiatr Dis Treat 3:847–853
Gangadhar BN, Kapur RL, Kalyanasundaram S (1982) Comparison of electroconvulsive therapy with imipramine in endogenous depression: a double blind study. Br J Psychiatry 141:367–371
Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661
Gelenberg AJ, Thase ME, Meyer RE, Goodwin FK, Katz MM, Kraemer HC, Potter WZ, Shelton RC, Fava M, Khan A, Trivedi MH, Ninan PT, Mann JJ, Bergeson S, Endicott J, Kocsis JH, Leon AC, Manji HK, Rosenbaum JF (2008) The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry 69:1513–1528
Geller B, Fox LW, Clark KA (1994) Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry 33:461–468
Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ (2005) Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32:1975–1985
Georgotas A, McCue RE, Hapworth W, Friedman E, Kim OM, Welkowitz J, Chang I, Cooper TB (1986) Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 21:1155–1166
Ghaemi SN (2008) Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disord 10:957–968
Ghanbari R, El MM, Blier P (2011) Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion. Psychopharmacology (Berl) 217:61–73
Giedke H, Schwarzler F (2002) Therapeutic use of sleep deprivation in depression. Sleep Med Rev 6:361–377
Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM (2004) Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161:1537–1547
Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL (2009) Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 374:1252–1261
Glen AI, Johnson AL, Shepherd M (1984) Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. Psychol Med 14:37–50
Goldberg JF (2003) When do antidepressants worsen the course of bipolar disorder? J Psychiatr Pract 9:181–194
Gomeni R, Lavergne A, Merlo-Pich E (2009) Modelling placebo response in depression trials using a longitudinal model with informative dropout. Eur J Pharm Sci 36:4–10
Gomeni R, Merlo-Pich E (2007) Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol 63:595–613
Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU (2008) ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol 18:535–549
Grandjean EM, Aubry JM (2009) Lithium: updated human knowledge using an evidence-based approach: Part I: clinical efficacy in bipolar disorder. CNS Drugs 23:225–240
Greden JF (2009) Treating depression and pain. J Clin Psychiatry 70:e16
Gross G, Xin X, Gastpar M (1991) Trimipramine: pharmacological reevaluation and comparison with clozapine. Neuropharmacology 30:1159–1166
Grote NK, Frank E (2003) Difficult-to-treat depression: the role of contexts and comorbidities. Biol Psychiatry 53:660–670
Grunze H (2005) Reevaluating therapies for bipolar depression. J Clin Psychiatry 66(Suppl 5):17–25
Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ (2002) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J Biol Psychiatry 3:115–124
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S (2010) The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 11:81–109
Guaiana G, Barbui C, Hotopf M (2003) Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev CD004186
Guaiana G, Barbui C, Hotopf M (2007) Amitriptyline for depression. Cochrane Database Syst Rev CD004186
Gupta RK, Moller HJ (2003) St. John’s Wort. An option for the primary care treatment of depressive patients? Eur Arch Psychiatry Clin Neurosci 253:140–148
Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V (2010) Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 25:305–314
Hameed U, Schwartz TL, Malhotra K, West RL, Bertone F (2005) Antidepressant treatment in the primary care office: outcomes for adjustment disorder versus major depression. Ann Clin Psychiatry 17:77–81
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
Hamoda HM, Osser DN (2008) The psychopharmacology algorithm project at the harvard south shore program: an update on psychotic depression. Harv Rev Psychiatry 16:235–247
Hasey G (2001) Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy. Can J Psychiatry 46:720–727
Healy D, Whitaker C (2003) Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci 28:331–337
Hegerl U, Hautzinger M, Mergl R, Kohnen R, Schutze M, Scheunemann W, Allgaier AK, Coyne J, Henkel V (2010) Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients’ choice arm. Int J Neuropsychopharmacol 13:31–44
Hegerl U, Mergl R (2009) The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences. J Psychopharmacol 24:445–448
Hegerl U, Pfeiffer-Gerschel T, Althaus D (2004) Elements for the effective treatment of patients with depressive disorders at the primary care level. MMW Fortschr Med 146(2):10, 12–10, 14
Hegerl U, Plattner A, Moller HJ (2004) Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s. Eur Arch Psychiatry Clin Neurosci 254:99–107
Hegerl U, Schönknecht P (2009) Subdiagnostic depression. Are there treatments with clinically relevant effects? Nervenarzt 80:532–539
Helmchen H (1974) Symptomatology of therapy-resistant depressions. Pharmakopsychiatr Neuropsychopharmakol 7:145–155
Hemmeter UM, Hemmeter-Spernal J, Krieg JC (2010) Sleep deprivation in depression. Expert Rev Neurother 10:1101–1115
Henkel V, Mergl R, Allgaier AK, Kohnen R, Möller HJ, Hegerl U (2006) Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res 141:89–101
Henkel V, Mergl R, Coyne JC, Kohnen R, Allgaier AK, Ruhl E, Möller HJ, Hegerl U (2004) Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences. J Affect Disord 83:237–242
Henkel V, Seemuller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M (2009) Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 115:439–449
Hirschfeld RM, Dunner DL, Keitner G, Klein DN, Koran LM, Kornstein SG, Markowitz JC, Miller I, Nemeroff CB, Ninan PT, Rush AJ, Schatzberg AF, Thase ME, Trivedi MH, Borian FE, Crits-Christoph P, Keller MB (2002) Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 51:123–133
Hollon SD, Jarrett RB, Nierenberg AA, Thase ME, Trivedi M, Rush AJ (2005) Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? J Clin Psychiatry 66:455–468
Iosifescu DV (2008) Prediction of response to antidepressants: is quantitative EEG (QEEG) an alternative? CNS Neurosci Ther 14:263–265
Iosifescu DV, Greenwald S, Devlin P, Mischoulon D, Denninger JW, Alpert JE, Fava M (2009) Frontal EEG predictors of treatment outcome in major depressive disorder. Eur Neuropsychopharmacol 19:772–777
Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, Holsboer F (2005) The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 29:1085–1093
Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Muller-Myhsok B (2009) A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66:966–975
Jensen TS, Finnerup NB (2009) Neuropathic pain treatment: a further step forward. Lancet 374:1218–1219
Joffe RT, Singer W, Levitt AJ, MacDonald C (1993) A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 50:387–393
Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB (1998) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55:694–700
Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A (1982) Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 39:1065–1069
Karasu TB, Gelenberg A, Merriam A, Wang P (2000) Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 157:1–45
Kasper S (2001) Hypericum perforatum–a review of clinical studies. Pharmacopsychiatry 34(Suppl 1):S51–S55
Kasper S, Calabrese JR, Johnson G, Tajima O, Vieta E, Viguera AC, Yatham LN, Young A (2008) International consensus group on the evidence-based pharmacologic treatment of bipolar I and II depression. J Clin Psychiatry 69:1632–1646
Kasper S, Gastpar M, Muller WE, Volz HP, Dienel A, Kieser M, Moller HJ (2008) Efficacy of St. John’s wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. Eur Arch Psychiatry Clin Neurosci 258:59–63
Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Bayle FJ (2010) Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 71:109–120
Kasper S, Hamon M (2009) Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry 10:117–126
Kasper S, Rogers SL, Madden PA, Joseph-Vanderpool JR, Rosenthal NE (1990) The effects of phototherapy in the general population. J Affect Disord 18:211–219
Kasper S, Rogers SL, Madden PA, Joseph-Vanderpool JR, Rosenthal NE (1990) The effects of phototherapy in the general population. J Affect Disord 18:211–219
Kasper S, Rogers SL, Yancey A, Schulz PM, Skwerer RG, Rosenthal NE (1989) Phototherapy in individuals with and without subsyndromal seasonal affective disorder. Arch Gen Psychiatry 46:837–844
Kasper S, Rogers SL, Yancey AL, Schulz PM, Skwerer RG, Rosenthal NE (1988) Phototherapy in subsyndromal seasonal affective disorder (S-SAD) and “diagnosed” controls. Pharmacopsychiatry 21:428–429
Katon W, Unutzer J, Russo J (2009) Major depression: the importance of clinical characteristics and treatment response to prognosis. Depress Anxiety
Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DR, Lock T, Burns RA, Robertson MM (1995) Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 166:80–86
Katz MM, Bowden CL, Frazer A (2010) Rethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioral elements. J Affect Disord 120:16–23
Katz MM, Houston JP, Brannan S, Bowden CL, Berman N, Swann AC, Frazer A (2004) A multivantaged behavioural method for measuring onset and sequence of the clinical actions of antidepressants. Int J Neuropsychopharmacol 7:471–479
Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J (2000) A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342:1462–1470
Kellner CH, Fink M, Knapp R, Petrides G, Husain M, Rummans T, Mueller M, Bernstein H, Rasmussen K, O’Connor K, Smith G, Rush AJ, Biggs M, McClintock S, Bailine S, Malur C (2005) Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am J Psychiatry 162:977–982
Kemp AH, Gordon E, Rush AJ, Williams LM (2008) Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 13:1066–1086
Kemp DE, Ganocy SJ, Brecher M, Carlson BX, Edwards S, Eudicone JM, Evoniuk G, Jansen W, Leon AC, Minkwitz M, Pikalov A, Stassen HH, Szegedi A, Tohen M, Van Willigenburg AP, Calabrese JR (2011) Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord 130:171–179
Kennedy SH, Lam RW, Cohen NL, Ravindran AV (2001) Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 46(Suppl 1):38S–58S
Ketter TA, Brooks JO, Hoblyn JC, Champion LM, Nam JY, Culver JL, Marsh WK, Bonner JC (2008) Effectiveness of lamotrigine in bipolar disorder in a clinical setting. J Psychiatr Res 43:13–23
Kieser M, Szegedi A (2005) Predicting stable treatment response in patients with major depression treated with hypericum extract WS 5570/5572. Pharmacopsychiatry 38:194–200
Kirchheiner J, Grundemann D, Schomig E (2006) Contribution of allelic variations in transporters to the phenotype of drug response. J Psychopharmacol 20:27–32
Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442–473
Kirsch I (2009) Antidepressants and the placebo response. Epidemiol Psichiatr Soc 2010(02/23):318–322
Kirsch I (2009) The emperor’s new drugs: exploding the antidepressant myth. The Bodley Head, London
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45
Kobayashi N, Sawamura T, Yoshida T, Yoshino A, Nomura S (2004) The effectiveness of lithium augmentation of milnacipran: preliminary data using the modified Japanese psychopharmacology algorithm. Nihon Shinkei Seishin Yakurigaku Zasshi 24:279–281
Korb AS, Hunter AM, Cook IA, Leuchter AF (2009) Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression. Clin Neurophysiol 120:1313–1319
Kornstein SG, Fava M, Jiang Q, Tourian KA (2009) Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo. Psychopharmacol Bull 42:21–35
Kragh-Sorensen P, Muller B, Andersen JV, Buch D, Stage KB (1995) Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study. J Clin Psychopharmacol 15:24S–30S
Kroenke K, Bair MJ, Damush TM, Wu J, Hoke S, Sutherland J, Tu W (2009) Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA 301:2099–2110
Kulkarni SK, Dhir A (2009) Current investigational drugs for major depression. Expert Opin Investig Drugs 18:767–788
Kupfer DJ, Charney DS (2003) Difficult-to-treat depression. Biol Psychiatry 53:633–634
Kurian BT, Trivedi MH, Grannemann BD, Claassen CA, Daly EJ, Sunderajan P (2009) A computerized decision support system for depression in primary care. Prim Care Companion J Clin Psychiatry 11:140–146
Laakmann G, Faltermaier-Temizel M, Bossert-Zaudig S, Baghai T (1996) Are benzodiazepines antidepressants? Psychopharmacology (Berl) 124:291–292
Laakmann G, Schüle C, Baghai TC, Kieser M (1998) St. John’s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31(Suppl 1):54–59
Lanz S, Maihofner C (2009) Symptoms and pathophysiological mechanisms of neuropathic pain syndromes. Nervenarzt 80:430–444
Larkin GL, Beautrais AL (2011) A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14:1127–1131
Lau MA (2008) New developments in psychosocial interventions for adults with unipolar depression. Curr Opin Psychiatry 21:30–36
Lee MS, Lim SW, Cha JH, Chung SK, Kim KS, Kasper S, Executive Commitee for the Korean Medication Algorithm Project for Major Depressive Disorder (2006) Korean medication algorithm for major depressive disorder. Int J Psychiatry Clin Pract 10:186–194
Lee RA, West RM, Wilson JD (2005) The response to sertraline in men with chronic pelvic pain syndrome. Sex Transm Infect 81:147–149
Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JT (1999) Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 14:329–337
Leonard BE (1988) Biochemical aspects of therapy-resistant depression. Br J Psychiatry 152:453–459
Leproult R, Van OA, L’hermite-Baleriaux M, Van CE, Copinschi G (2005) Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 63:298–304
Leucht S, Kissling W, Davis JM (2009) How to read and understand and use systematic reviews and meta-analyses. Acta Psychiatr Scand 119:443–450
Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S (2009) Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res 169:132–138
Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, McCracken JT, Fava M, Iosifescu D, Greenwald S (2009) Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study. Psychiatry Res 169:124–131
Leuchter AF, Husain MM, Cook IA, Trivedi MH, Wisniewski SR, Gilmer WS, Luther JF, Fava M, Rush AJ (2009) Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med 40:239–251
Lima MS, Moncrieff J (2000) Drugs versus placebo for dysthymia. Cochrane Database Syst Rev CD001130
Lingjaerde O, Jorgensen J, Storen R, Thomle S, Wendt RL, Ruud LE, Schetelig E, Sveaas HK, Leivestad O (1995) A double-blind comparison of moclobemide and doxepin in depressed general practice patients. Acta Psychiatr Scand 92:125–131
Loo H, Dalery J, Macher JP, Payen A (2002) Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders. Encephale 28:356–362
Loo H, Dalery J, Macher JP, Payen A (2003) Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. Encephale 29:165–171
Lutz W, Stulz N, Kock K (2009) Patterns of early change and their relationship to outcome and follow-up among patients with major depressive disorders. J Affect Disord 118:60–68
Lyness JM (2008) Naturalistic outcomes of minor and subsyndromal depression in older primary care patients. Int J Geriatr Psychiatry 23:773–781
Lyness JM, Chapman BP, McGriff J, Drayer R, Duberstein PR (2009) One-year outcomes of minor and subsyndromal depression in older primary care patients. Int Psychogeriatr 21:60–68
Maina G, Rosso G, Bogetto F (2009) Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: long-term results. J Affect Disord 114:200–207
Mallinger AG, Frank E, Thase ME, Barwell MM, Diazgranados N, Luckenbaugh DA, Kupfer DJ (2009) Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior? Psychopharmacol Bull 42:64–74
Malt UF (2002) The antidepressant debate continues. Br J Psychiatry 181:531
Malt UF, Robak OH, Madsbu HP, Bakke O, Loeb M (1999) The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: randomised double blind study. BMJ 318:1180–1184
Marangell LB, Dennehy EB, Miyahara S, Wisniewski SR, Bauer MS, Rapaport MH, Allen MH (2009) The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD. J Affect Disord 114:58–67
Mattia C, Paoletti F, Coluzzi F, Boanelli A (2002) New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol 68:105–114
McAllister-Williams RH (2008) Do antidepressants work? A commentary on “Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration” by Kirsch et al. Evid Based Ment Health 2008(08/02):66–68
McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH (2010) A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 71:163–174
McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 163:1531–1541
Melander H, Salmonson T, Abadie E, van Zwieten-Boot B (2008) A regulatory Apologia—a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623–627
Meyer RE, Salzman C, Youngstrom EA, Clayton PJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM Jr, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV (2010) Suicidality and risk of suicide-definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 71:e1–e21
Mihaljevic-Peles A, Sagud M, Bozina N, Zivkovic M (2008) Pharamacogenetics and antidepressant treatment in integrative psychiatry perspective. Psychiatr Danub 20:399–401
Milak MS, Parsey RV, Lee L, Oquendo MA, Olvet DM, Eipper F, Malone K, Mann JJ (2009) Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment. Psychiatry Res 173:63–70
Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM (2008) Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord 10:144–152
Moja PL, Cusi C, Sterzi RR, Canepari C (2005) Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev CD002919
Molenaar PJ, Dekker J, Van R, Hendriksen M, Vink A, Schoevers RA (2007) Does adding psychotherapy to pharmacotherapy improve social functioning in the treatment of outpatient depression? Depress Anxiety 24:553–562
Möller HJ (2006) Evidence for beneficial effects of antidepressants on suicidality in depressive patients: a systematic review. Eur Arch Psychiatry Clin Neurosci 256:329–343
Möller HJ (2006) Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review. Eur Arch Psychiatry Clin Neurosci 256:476–496
Möller HJ (2008) Isn’t the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451–455
Möller HJ (2009) Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry 10:180–195
Möller HJ (2009) Is evidence sufficient for evidence-based medicine? Eur Arch Psychiatry Clin Neurosci 2009(11/13):S167–S172
Möller HJ, Broich K (2010) Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. Eur Arch Psychiatry Clin Neurosci 2009(11/06):3–16
Möller HJ, Grunze H, Broich K (2006) Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci 256:1–16
Möller HJ, Maier W (2007) Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making. Nervenarzt 78:1014–1027
Möller HJ, Maier W (2010) Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci 260:25–39
Moncrieff J, Wessely S, Hardy R (2004) Active placebos versus antidepressants for depression. Cochrane Database Syst Rev CD003012
Montgomery DB, Roberts A, Green M, Bullock T, Baldwin D, Montgomery SA (1994) Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts. Eur Arch Psychiatry Clin Neurosci 244:211–215
Montgomery SA (1999) New developments in the treatment of depression. J Clin Psychiatry 60(Suppl 14):10–15
Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389
Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lepine JP, Moller HJ, Nutt DJ, Rouillon F, Schatzberg AF, Thase ME (2007) Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323–329
Montgomery SA, Kasper S (2007) Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 22:283–291
Montgomery SA, Möller HJ (2009) Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 24:111–118
Montgomery SA, Rasmussen JG, Tanghoj P (1993) A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 8:181–188
Moreno SG, Sutton AJ, Turner EH, Abrams KR, Cooper NJ, Palmer TM, Ades AE (2009) Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ 339:b2981
Mukai Y, Tampi RR (2009) Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. Clin Ther 31:945–961
Mulder RT, Joyce PR, Luty SE (2003) The relationship of personality disorders to treatment outcome in depressed outpatients. J Clin Psychiatry 64:259–264
Mulder RT, Watkins WG, Joyce PR, Luty SE (2003) Age may affect response to antidepressants with serotonergic and noradrenergic actions. J Affect Disord 76:143–149
Mulert C, Juckel G, Augustin H, Hegerl U (2002) Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression. Clin Neurophysiol 113:1566–1572
Mulert C, Juckel G, Brunnmeier M, Karch S, Leicht G, Mergl R, Moller HJ, Hegerl U, Pogarell O (2007) Prediction of treatment response in major depression: integration of concepts. J Affect Disord 98:215–225
Muller JE, Wentzel I, Koen L, Niehaus DJ, Seedat S, Stein DJ (2008) Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. Int Clin Psychopharmacol 23:43–48
Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11:680–684
Muller-Oerlinghausen B, Lewitzka U (2010) Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology 62:43–49
Mulsant BH, Sweet RA, Rosen J, Pollock BG, Zubenko GS, Flynn T, Begley AE, Mazumdar S, Reynolds CF III (2001) A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry 62:597–604
Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA (2009) Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev CD006529
National Collaborating Centre for Mental Health (2009) London, National Institute for Health and Clinical Excellence (NICE). http://guidance.nice.org.uk/CG90. Accessed 7 Dec 2009
National Institute for Clinical Excellence (2004) http://www.nice.org.uk/nicemedia/pdf/CG23fullguideline.pdf. Accessed 1 Dec 2010
National Institute of Mental Health (1976) 028 CGI. Clinical global impressions. In: Guy W, Bonato RR (eds.) Manual for the EDCEU assessment battery, 2 Rev Chevy Chase, Maryland, pp 12-1–12-6
Nelson JC, Docherty JP, Henschen GM, Kasper S, Nierenberg AA, Ward NG (1995) Algorithms for the treatment of subtypes of unipolar major depression. Psychopharmacol Bull 31:475–482
Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980–991
Nelson JC, Pikalov A, Berman RM (2008) Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat 4:937–948
Nelson JP, Benjamin L (1989) Efficacy and safety of combined ECT and tricyclic antidepressant drugs in the treatment of depressed geriatric patients. Convuls Ther 5:321–329
Nemeroff CB (2005) Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 66(Suppl 8):13–21
Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD (2001) Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 158:906–912
Nierenberg AA (2009) Diagnosing and treating patients with symptoms of depression. J Clin Psychiatry 70:e05
Nierenberg AA, Amsterdam JD (1990) Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 51(Suppl):39–47
Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163:1519–1530
Novick JS, Stewart JW, Wisniewski SR, Cook IA, Manev R, Nierenberg AA, Rosenbaum JF, Shores-Wilson K, Balasubramani GK, Biggs MM, Zisook S, Rush AJ (2005) Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry 66:1002–1011
Pacchiarotti I, Valenti M, Colom F, Rosa AR, Nivoli AM, Murru A, Moreno JS, Vieta E (2010) Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J Affect Disord 129:321–326
Pae CU, Tharwani H, Marks DM, Masand PS, Patkar AA (2009) Atypical depression: a comprehensive review. CNS Drugs 23:1023–1037
Pail G, Huf W, Winkler-Pjrek E, Winkler D, Willeit M, Praschak-Rieder N, Kasper S (2010) Bright light therapy in the treatment of mood disorders. Neuropsychobiology 64:152–162
Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C (2004) Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 61:714–719
Papakostas GI (2007) Augmentation strategies in the treatment of major depressive disorder. Examining the evidence on augmentation with atypical antipsychotics. CNS Spectr 12:10–12
Papakostas GI (2009) Pharmacologic and therapeutic strategies in treatment-resistant depression. Switching antidepressants vs. conventional augmentation strategies. CNS Spectr 14:11–14
Papakostas GI, Fava M (2006) A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatry 51:783–790
Papakostas GI, Fava M, Thase ME (2008) Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 63:699–704
Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (2007) Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62:1217–1227
Parker G (2007) Defining melancholia: the primacy of psychomotor disturbance. Acta Psychiatr Scand Suppl 433:21–30
Parker G, Parker I, Brotchie H, Stuart S (2006) Interpersonal psychotherapy for depression? The need to define its ecological niche. J Affect Disord 95:1–11
Parker G, Roy K, Eyers K (2003) Cognitive behavior therapy for depression? Choose horses for courses. Am J Psychiatry 160:825–834
Parker G, Tully L, Olley A, Hadzi-Pavlovic D (2006) SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. J Affect Disord 92:205–214
Patten SB (2006) Does almost everybody suffer from a bipolar disorder? Can J Psychiatry 51:6–8
Paul R, Schaaff N, Padberg F, Moller HJ, Frodl T (2009) Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry 10:241–244
Paykel ES, Freeling P, Hollyman JA (1988) Are tricyclic antidepressants useful for mild depression? A placebo controlled trial. Pharmacopsychiatry 21:15–18
Paykel ES, Hollyman JA, Freeling P, Sedgwick P (1988) Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord 14:83–95
Peet M (1994) Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 164:549–550
Perugi G, Akiskal HS, Lattanzi L, Cecconi D, Mastrocinque C, Patronelli A, Vignoli S, Bemi E (1998) The high prevalence of “soft” bipolar (II) features in atypical depression. Compr Psychiatry 39:63–71
Pezawas L, Angst J, Kasper S (2005) Recurrent brief depression revisited. Int Rev Psychiatry 17:63–70
Pezawas L, Stamenkovic M, Kasper S (2001) Recurrent brief depressive episodes. Epidemiology, clinical aspects, diagnosis and therapy. Nervenarzt 72:169–180
Pjrek E, Winkler D, Stastny J, Konstantinidis A, Heiden A, Kasper S (2004) Bright light therapy in seasonal affective disorder—does it suffice? Eur Neuropsychopharmacol 14:347–351
Pogarell O, Juckel G, Norra C, Leicht G, Karch S, Schaaff N, Folkerts M, Ibrahim A, Mulert C, Hegerl U (2007) Prediction of clinical response to antidepressants in patients with depression: neurophysiology in clinical practice. Clin EEG Neurosci 38:74–77
Poirier MF, Boyer P (1999) Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 175:12–16
Post RM, Altshuler LL, Frye MA, Suppes T, Rush AJ, Keck PE Jr, McElroy SL, Denicoff KD, Leverich GS, Kupka R, Nolen WA (2001) Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 3:259–265
Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, Suppes T, McElroy S, Keck PE, Denicoff KD, Grunze H, Walden J, Kitchen CM, Mintz J (2006) Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 189:124–131
Price LH, Conwell Y, Nelson JC (1983) Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 140:318–322
Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66:522–526
Prien RF, Klett CJ, Caffey EM Jr (1973) Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry 29:420–425
Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE (1984) Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 41:1096–1104
Rampello L, Chiechio S, Nicoletti G, Alvano A, Vecchio I, Raffaele R, Malaguarnera M (2004) Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berl) 173:73–78
Ravaris CL, Robinson DS, Ives JO, Nies A, Bartlett D (1980) Phenelzine and amitriptyline in the treatment of depression. A comparison of present and past studies. Arch Gen Psychiatry 37:1075–1080
Ravindran LN, Ravindran AV (2007) Lamotrigine in the treatment of recurrent brief depression. Int Clin Psychopharmacol 22:121–123
Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X (2008) Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 69:1228–1336
Reeves RR, Ladner ME (2010) Antidepressant-induced suicidality: an update. CNS Neurosci Ther 16:227–234
Riedel M, Moller HJ, Obermeier M, Schennach-Wolff R, Bauer M, Adli M, Kronmuller K, Nickel T, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Seemuller F (2010) Response and remission criteria in major depression—A validation of current practice. J Psychiatr Res 44:1063–1068
Riemann D, Voderholzer U, Cohrs S, Rodenbeck A, Hajak G, Ruther E, Wiegand MH, Laakmann G, Baghai T, Fischer W, Hoffmann M, Hohagen F, Mayer G, Berger M (2002) Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 35:165–174
Rihmer Z, Akiskal H (2006) Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 94:3–13
Rocca P, Fonzo V, Ravizza L, Rocca G, Scotta M, Zanalda E, Bogetto F (2002) A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord 70:313–317
Rohan KJ, Roecklein KA, Lacy TJ, Vacek PM (2009) Winter depression recurrence one year after cognitive-behavioral therapy, light therapy, or combination treatment. Behav Ther 40:225–238
Rohan KJ, Roecklein KA, Tierney LK, Johnson LG, Lippy RD, Lacy TJ, Barton FB (2007) A randomized controlled trial of cognitive-behavioral therapy, light therapy, and their combination for seasonal affective disorder. J Consult Clin Psychol 75:489–500
Rohland BM, Carroll BT, Jacoby RG (1993) ECT in the treatment of the catatonic syndrome. J Affect Disord 29:255–261
Rosenthal NE (2009) Issues for DSM-V: seasonal affective disorder and seasonality. Am J Psychiatry 166:852–853
Rosenthal NE, Sack DA, Carpenter CJ, Parry BL, Mendelson WB, Wehr TA (1985) Antidepressant effects of light in seasonal affective disorder. Am J Psychiatry 142:163–170
Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT (1993) Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 54:338–342
Rudolf GA, Tolle R (1978) Sleep deprivation and circadian rhythm in depression. Psychiatr Clin (Basel) 11:198–212
Rush AJ (2007) STAR*D: what have we learned? Am J Psychiatry 2007(02/03):201–204
Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Trivedi MH, Suppes T, Miller AL, Biggs MM, Shores-Wilson K, Witte BP, Shon SP, Rago WV, Altshuler KZ (2003) Texas medication algorithm project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry 64:357–369
Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142
Rush AJ, Thase ME (1997) Strategies and tactics in the treatment of chronic depression. J Clin Psychiatry 58(Suppl 13):14–22
Rush AJ, Thase ME, Dube S (2003) Research issues in the study of difficult-to-treat depression. Biol Psychiatry 53:743–753
Rush AJ, Trivedi M, Fava M (2003) Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry 160:237
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917
Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242
Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, Nierenberg AA (2009) STAR*D: revising conventional wisdom. CNS Drugs 23:627–647
Saarto T, Wiffen PJ (2005) Antidepressants for neuropathic pain. Cochrane Database Syst Rev CD005454
Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF (1994) A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 55:391–393
Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME (2007) Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356:1711–1722
Sackeim HA (2001) The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62(Suppl 16):10–17
Sackeim HA, Dillingham EM, Prudic J, Cooper T, McCall WV, Rosenquist P, Isenberg K, Garcia K, Mulsant BH, Haskett RF (2009) Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Arch Gen Psychiatry 66:729–737
Sado M, Knapp M, Yamauchi K, Fujisawa D, So M, Nakagawa A, Kikuchi T, Ono Y (2009) Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Aust N Z J Psychiatry 43:539–547
Santen G, Danhof M, Pasqua OD (2009) Sensitivity of the montgomery asberg depression rating scale to response and its consequences for the assessment of efficacy. J Psychiatr Res 43:1049–1056
Sartorius N, Baghai TC, Baldwin DS, Barrett B, Brand U, Fleischhacker W, Goodwin G, Grunze H, Knapp M, Leonard BE, Lieberman J, Nakane Y, Pinder RM, Schatzberg AF, Svestka J, Baumann P, Ghalib K, Markowitz JC, Padberg F, Fink M, Furukawa T, Fountoulakis KN, Jensen P, Kanba S, Riecher-Rossler A (2007) Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol 10(Suppl 1):S1–207
Schaffer A, Zuker P, Levitt A (2006) Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 96:95–99
Schreiber S, Frishtick R, Volis I, Rubovitch V, Pick CG, Weizman R (2009) The antinociceptive properties of reboxetine in acute pain. Eur Neuropsychopharmacol 19:735–739
Schüle C, Baghai TC, Eser D, Hafner S, Born C, Herrmann S, Rupprecht R (2009) The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. PLoS One 4:e4324
Seemüller F, Möller HJ, Obermeier M, Adli M, Bauer M, Kronmuller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Riedel M (2010) Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials. J Clin Psychiatry 71:1425–1433
Seemüller F, Riedel M, Obermeier M, Bauer M, Adli M, Kronmuller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Dichgans E, Bottlander R, Musil R, Möller HJ (2010) Outcomes of 1014 naturalistically treated inpatients with major depressive episode. Eur Neuropsychopharmacol 29:346–355
Seemüller F, Wolff RS, Obermeier M, Henkel V, Möller HJ, Riedel M (2009) Does early improvement in major depression protect against treatment emergent suicidal ideation? J Affect Disord 124:183–186
Seo HJ, Chiesa A, Lee SJ, Patkar AA, Han C, Masand PS, Serretti A, Pae CU (2011) Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol 34:39–47
Seyringer ME, Kasper S (2009) Ranking antidepressants. Lancet 373:1760–1761
Shelton RC, Andorn AC, Mallinckrodt CH, Wohlreich MM, Raskin J, Watkin JG, Detke MJ (2007) Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol 22:348–355
Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, Tohen M (2004) Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther 26:125–134
Shirani A, St Louis EK (2009) Illuminating rationale and uses for light therapy. J Clin Sleep Med 5:155–163
Shulman KI, Fischer HD, Herrmann N, Huo CY, Anderson GM, Rochon PA (2009) Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry 70:1681–1686
Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J (1999) An international study of the relation between somatic symptoms and depression. N Engl J Med 341:1329–1335
Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S, Detke M, Backonja M (2009) A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 16:1041–1048
Slotema CW, Blom JD, Hoek HW, Sommer IE (2010) Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? a meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 71:873–884
Sogaard J, Lane R, Latimer P, Behnke K, Christiansen PE, Nielsen B, Ravindran AV, Reesal RT, Goodwin DP (1999) A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 13:406–414
Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J (1999) Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 9:83–91
Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J (2007) Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 68:1062–1070
Starkstein SE, Petracca G, Teson A, Chemerinski E, Merello M, Migliorelli R, Leiguarda R (1996) Catatonia in depression: prevalence, clinical correlates, and validation of a scale. J Neurol Neurosurg Psychiatry 60:326–332
Stassen H, Angst J, Delini-Stula A (1998) Onset of improvement under fluoxetine and moclobemide. Eur Psychiatry 13:128–133
Stassen HH, Angst J (1998) Delayed onset of action of antidepressants- fact or fiction? CNS Drugs 9:177–184
Stassen HH, Angst J, Delini-Stula A (1996) Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 29:87–96
Stassen HH, Angst J, Delini-Stula A (1997) Delayed onset of action of antidepressant drugs? Survey of recent results. Eur Psychiatry 12:166–176
Stassen HH, Angst J, Delini-Stula A (1997) Onset of action under antidepressant treatment. Eur Psychiatry 12:163–165
Stassen HH, Angst J, ini-Stula A (1996) Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 29:87–96
Stassen HH, Angst J, ini-Stula A (1997) Onset of action under antidepressant treatment. Eur Psychiatry 12:163–165
Stassen HH, Angst J, ini-Stula A (1999) Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement. Pharmacopsychiatry 32:56–60
Stassen HH, Delini-Stula A, Angst J (1993) Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 3:127–135
Stewart JW, McGrath PJ, Quitkin FM, Klein DF (2007) Atypical depression: current status and relevance to melancholia. Acta Psychiatr Scand 115:58–71
Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Gersons BP, van Strik R, Broekmans AW (2001) Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 11:173–180
Stübner S, Grohmann R, von Stralendorff I, Ruther E, Moller HJ, Muller-Oerlinghausen B, Engel RR, Horvath A, Greil W (2010) Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. J Clin Psychiatry 71:1293–1307
Szegedi A, Jansen WT, Van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME (2009) Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 70:344–353
Tadic A, Helmreich I, Mergl R, Hautzinger M, Kohnen R, Henkel V, Hegerl U (2010) Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord 120:86–93
Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249–258
Taylor MA, Fink M (2003) Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 160:1233–1241
Tayor MA, Fink M (2006) Melancholia: the diagnosis, pathophysiology and treatment of depressive illness. Cambridge University Press, Cambridge
Thase ME (1999) Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 60(Suppl 17):28–31
Thase ME (2003) Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry 64(Suppl 13):18–25
Thase ME (2007) Recognition and diagnosis of atypical depression. J Clin Psychiatry 68(Suppl 8):11–16
Thase ME (2007) STEP-BD and bipolar depression: what have we learned? Curr Psychiatry Rep 9:497–503
Thase ME (2008) Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat 4:11–21
Thase ME, Greenhouse JB, Frank E, Reynolds CF III, Pilkonis PA, Hurley K, Grochocinski V, Kupfer DJ (1997) Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 54:1009–1015
Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR (2006) Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26:600–609
Thase ME, Rush AJ (1997) When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58(Suppl 13):23–29
Thase ME, Trivedi MH, Rush AJ (1995) MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12:185–219
The Cochrane Collaboration (2009) Accessed <[28] Access Date>
Thompson SG, Pocock SJ (1991) Can meta-analyses be trusted? Lancet 338:1127–1130
Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079–1088
Tran PV, Bymaster FP, McNamara RK, Potter WZ (2003) Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 23:78–86
Trivedi MH, Daly EJ (2007) Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend 88(Suppl 2):S61–S71
Trivedi MH, DeBattista C, Fawcett J, Nelson C, Osser DN, Stein D, Jobson K (1998) Developing treatment algorithms for unipolar depression in cyberspace: international psychopharmacology algorithm project (IPAP). Psychopharmacol Bull 34:355–359
Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Key T, Biggs MM, Shores-Wilson K, Witte B, Suppes T, Miller AL, Altshuler KZ, Shon SP (2004) Clinical results for patients with major depressive disorder in the Texas medication algorithm project. Arch Gen Psychiatry 61:669–680
Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM (2008) Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry 69:1928–1936
Turner E, Moreno SG, Sutton AJ (2009) Ranking antidepressants. Lancet 373:1760–1762
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358:252–260
U.S.Food and Drug Administration (FDA) (5-2-2007) http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096273.htm. Accessed 31 Jan 2011
U.S. Food and Drug Administration (FDA) (7-8-2009) http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161696.htm. Accessed 1 Feb 2011
Uchida H, Takeuchi H, Suzuki T, Nomura K, Watanabe K, Kashima H (2005) Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. J Clin Psychopharmacol 25:545–551
Uebelhack R, Gruenwald J, Graubaum HJ, Busch R (2004) Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther 21:265–275
Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, Hauser J, Maier W, Kozel D, Henigsberg N, Barreto M, Placentino A, Dernovsek MZ, Schulze TG, Kalember P, Zobel A, Czerski PM, Larsen ER, Souery D, Giovannini C, Gray JM, Lewis CM, Farmer A, Aitchison KJ, McGuffin P, Craig I (2009) Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9:225–233
van Calker D, Zobel I, Dykierek P, Deimel CM, Kech S, Lieb K, Berger M, Schramm E (2009) Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. J Affect Disord 114:243–253
van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, Nolen WA (2009) Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 70:223–231
Versiani M (1998) Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. J Affect Disord 51:323–332
Vieta E, Martinez-Aran A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M (2002) A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clini Psychiatry 63:508–512
Voderholzer U, Valerius G, Schaerer L, Riemann D, Giedke H, Schwarzler F, Berger M, Wiegand M (2003) Is the antidepressive effect of sleep deprivation stabilized by a three day phase advance of the sleep period? A pilot study. Eur Arch Psychiatry Clin Neurosci 253:68–72
Volz HP, Laux P (2000) Potential treatment for subthreshold and mild depression: a comparison of St. John’s wort extracts and fluoxetine. Compr Psychiatry 41:133–137
Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287:1840–1847
Waring DR (2008) The antidepressant debate and the balanced placebo trial design: an ethical analysis. Int J Law Psychiatry 2008(10/29):453–462
Weissman MM (1979) The psychological treatment of depression. Evidence for the efficacy of psychotherapy alone, in comparison with, and in combination with pharmacotherapy. Arch Gen Psychiatry 36:1261–1269
Weissman MM, Prusoff BA, Dimascio A, Neu C, Goklaney M, Klerman GL (1979) The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. Am J Psychiatry 136:555–558
Williams WR, Richards JP, Ameen JR, Davies J (2007) Recurrent brief depression and personality traits in allergy, anxiety and premenstrual syndrome patients: a general practice survey. Med Sci Monit 13:CR118–CR124
Winkler D, Willeit M, Praschak-Rieder N, Lucht MJ, Hilger E, Konstantinidis A, Stastny J, Thierry N, Pjrek E, Neumeister A, Moller HJ, Kasper S (2002) Changes of clinical pattern in seasonal affective disorder (SAD) over time in a German-speaking sample. Eur Arch Psychiatry Clin Neurosci 252:54–62
Wirz-Justice A, Benedetti F, Berger M, Lam RW, Martiny K, Terman M, Wu JC (2005) Chronotherapeutics (light and wake therapy) in affective disorders. Psychol Med 35:939–944
Wirz-Justice A, Van den Hoofdakker RH (1999) Sleep deprivation in depression: what do we know, where do we go? Biol Psychiatry 46:445–453
Wisniewski SR, Rush AJ, Nierenberg AA, Gaynes BN, Warden D, Luther JF, McGrath PJ, Lavori PW, Thase ME, Fava M, Trivedi MH (2009) Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 166:599–607
Workman EA, Short DD (1993) Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J Clin Psychiatry 54:5–12
World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva, Switzerland
Wu JC, Bunney WE (1990) The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 147:14–21
Wu JC, Bunney WE (1990) The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 147:14–21
Wu JC, Kelsoe JR, Schachat C, Bunney BG, DeModena A, Golshan S, Gillin JC, Potkin SG, Bunney WE (2009) Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 66:298–301
Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O’Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F (2009) Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 11:225–255
Yerevanian BI, Koek RJ, Feusner JD, Hwang S, Mintz J (2004) Antidepressants and suicidal behaviour in unipolar depression. Acta Psychiatr Scand 110:452–458
Yoshida K, Higuchi H, Kamata M, Takahashi H, Inoue K, Suzuki T, Itoh K, Ozaki N (2007) The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol 21:650–656
Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB (2004) Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 161:1575–1580
Yoshimura M, Furue H (2006) Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord. J Pharmacol Sci 101:107–117
Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M (2010) A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 71:150–162
Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I (2000) Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 157:124–126
Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E (1996) Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 153:1631–1633
Zanardi R, Franchini L, Gasperini M, Smeraldi E, Perez J (1997) Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study. Int Clin Psychopharmacol 12:195–197
Zanardi R, Smeraldi E (2005) A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 16:281–287
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864
Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M (2001) Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J Psychiatr Res 35:83–94
Zullino D, Baumann P (2001) Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 34:119–127
Conflicts of interest
T.C. Baghai accepted paid speaking engagements and acted as a consultant for Astra-Zeneca, Glaxo-Smith-Kline, Janssen-Cilag, Organon, Pfizer and Servier. M. Bauer has received Grant/Research Support from The Stanley Medical Research Institute, NARSAD and the European Commission (FP7). He is a consultant for AstraZeneca, Lilly, Servier, Lundbeck, Bristol-Myers Squibb and Otsuka, and has received Speaker Honoraria from AstraZeneca, Lilly, GlaxoSmithKline, Lundbeck, GlaxoSmithKline, Bristol-Myers Squibb and Otsuka. D. Baldwin holds or has held grants from Cephalon, GlaxoSmithKline, Lilly, Lundbeck, Pharmacia and Wyeth; has received honoraria from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Lilly, Lundbeck, Pharmacia, Pierre Fabre, Pfizer, Servier and Wyeth; and has served on advisory boards for AstraZeneca, GlaxoSmithKline, Grunenthal, Lilly, Lundbeck, Organon, Pierre Fabre, Pfizer and Servier. P. Blier received honoraria for speaking engagements, advisory boards, and/or investigator-initiated grants from Angelini, Astra-Zeneca, Bristol Myers Squibb, Eli Lilly, Euthymics, Janssen, Labopharm, Lundbeck, Merck, Organon, Pfizer, Pierre Fabre, Schering-Plough, Servier, Takeda, Wyeth. G.M.Goodwin holds or has held grants from Bailly Thomas charity, Medical Research Council, NIHR, Servier; has received honoraria from AstraZeneca, BMS, Lundbeck, Sanofi-Aventis, Servier, holds shares in P1vital ltd; has served on advisory boards for AstraZeneca, BMS, Boehringer Ingelheim, Cephalon, Janssen-Cilag, Lilly, Lundbeck, P1Vital, Servier, Shering Plough, Wyeth and acted as an expert witness for Lilly and Servier. K.N. Fountoulakis has received grant/research support from Eli Lilly, Bristol-Myers Squibb, and Servier; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb and Servier, Janssen, and has given lectures for AstraZeneca, Eli Lily, Janssen, Servier, and Bristol-Myers Suibb. S. Kasper has received grant/research support from Eli Lilly, Lundbeck, Bristol-Myers Squibb, GlaxoSmithKline, Organon, Sepracor and Servier; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Organon, Schwabe, Sepracor, Servier, Janssen, and Novartis; and has served on speakers’ bureaus for AstraZeneca, Eli Lily, Lundbeck, Schwabe, Sepracor, Servier, Pierre Fabre, and Janssen. U.F. Malt has been paid for lecturing about treatment of mood disorders by Astra-Zeneca, GSK; Lilly and Lundbeck; and received honorarium by the Norwegian government’s Directorate of Health, for beeing member of task forces providing national treatment guidelines for Depression and Bipolar disorders respectively. D. Stein has received research grants and/or consultancy honoraria from Abbott, Astrazeneca, Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Takeda, Tikvah, and Wyeth. H.-J. Möller has received grant/research support, is member of advisory boards or has served as a speaker for AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Novartis, Organon, Pfizer, Sanofi-Aventis, Schering-Plough, Schwabe, Sepracor, Servier and Wyeth. B.E. Leonard, and M. Versiani had no conflicts of interest to declare.
This supplement was not sponsored by outside commercial interest. It was funded entirely by the authors.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The Section of Pharmacopsychiatry World Psychiatric Association is given in the Appendix.
Appendix: Section of Pharmacopsychiatry World Psychiatric Association
Appendix: Section of Pharmacopsychiatry World Psychiatric Association
Altamura C, Andreassen OA, Aarsland D, Baghai TC, Baldwin DS, Baron D, Bauer M, Belmaker RH, Blier P, Boyer P, Bunney WE, Burrows G, Fleischhacker W, Flores D, Fountoulakis KN, Gattaz WF, Goodwin G, Heinze G, Hindmarch I, Hoschl C, Kasper S, Sorensen PK, Langer SZ, Leonard B, Lopez-Ibor JJ, Malt U (co-chair), Millet B, Möller HJ (chair), Monti J, Müller-Oerlinghausen B, Okasha A, Olie JP, Paykel ES, Racagni G, Renshaw P, Rosenberg R, Rutz W, Saletu B, Sedvall G, Singh B (secretary), Stein DJ, Tandon R, Versiani M, Vieta E, Wegener G, Zohar J.
Rights and permissions
About this article
Cite this article
Baghai, T.C., Blier, P., Baldwin, D.S. et al. General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 261 (Suppl 3), 207–245 (2011). https://doi.org/10.1007/s00406-011-0259-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-011-0259-6